Who
June Sherie Almenoff
Director
Company insider
Files Form 4 as: Director, Actinium Pharmaceuticals, Inc. (Delaware); Director, Tenax Therapeutics; Director, Avalo Therapeutics; Director, Brainstorm Cell Therapeutics; COO and Chief Medical Officer, Innovate Biopharmaceuticals; Director, Ohr Pharmaceutical; President, Furiex Pharmaceuticals.
In numbers
- Trades disclosed
- 80
- Buys
- 20
- Sells
- 1
- Bought
- $334K
- Sold
- $13.3M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 17 Jun 2010
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | TENX Tenax Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | TENX Tenax Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 18 Nov 2025filed 20 Nov 2025 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K1,900 at $7.52 | filing |
| 18 Nov 2025filed 19 Nov 2025 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K1,900 at $7.52 | filing |
| 17 Nov 2025filed 20 Nov 2025 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Bought | $66593 at $7.15 | filing |
| 17 Nov 2025filed 19 Nov 2025 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Bought | $66593 at $7.15 | filing |
| 1 Jul 2025filed 3 Jul 2025 | TENX Tenax Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 28 Mar 2025filed 1 Apr 2025 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,167 at $0.00 | filing |
| 28 Mar 2025filed 1 Apr 2025 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,167 | filing |
| 10 Dec 2024filed 12 Dec 2024 | TENX Tenax Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 13 Nov 2024filed 14 Nov 2024 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,500500 at $13.00 | filing |
| 12 Nov 2024filed 14 Nov 2024 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,250500 at $12.50 | filing |
| 1 Nov 2024filed 5 Nov 2024 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 13 Aug 2024filed 14 Aug 2024 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,600 at $0.00 | filing |
News
Tenax Therapeutics (NASDAQ:TENX) Stock: Insider Adar1 Capital Management, Llc Acquires 336,528 SharesTENX · dailypolitical.com · 21 Oct 2026
0 headlines in the last 90 days name June Sherie Almenoff; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.